Department of Medicine and Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Aab Cardiovascular Research Institute, Rochester, New York 14642, USA.
J Clin Invest. 2012 Jan;122(1):30-2. doi: 10.1172/JCI61467. Epub 2011 Dec 27.
Cardiac ischemia-reperfusion (I-R) injury occurs upon prompt restoration of blood flow to the ischemic myocardium after an acute myocardial infarction. Interestingly, many of the features of I-R injury are related to impaired mitochondrial signaling and mitochondrial dysfunction. Restoring cardiac energy bioavailability and reduction-oxidation (redox) signaling are therefore important in recovery after I-R injury. In this issue of the JCI, Yoshioka and colleagues describe an important and unexpected role for thioredoxin-interacting protein (TXNIP) in the control of mitochondrial respiration and cell energy metabolism. Their findings could open the door for development of TXNIP-targeted therapeutic approaches for the treatment of cardiac I-R injury.
心肌缺血再灌注(I-R)损伤发生在急性心肌梗死后缺血心肌血流迅速恢复时。有趣的是,I-R 损伤的许多特征与受损的线粒体信号和线粒体功能障碍有关。因此,在 I-R 损伤后恢复过程中,恢复心脏能量生物利用度和氧化还原(redox)信号很重要。在本期 JCI 中,Yoshioka 及其同事描述了硫氧还蛋白相互作用蛋白(TXNIP)在控制线粒体呼吸和细胞能量代谢中的重要且意外的作用。他们的发现可能为开发针对 TXNIP 的治疗方法治疗心脏 I-R 损伤开辟道路。